Cargando…

Chemotherapy Options beyond the First Line in HER-Negative Metastatic Breast Cancer

Despite the recent advances in the biological understanding of breast cancer (BC), chemotherapy still represents a key component in the armamentarium for this disease. Different agents are available as mono-chemotherapy options in patients with locally advanced or metastatic BC (MBC) who progress af...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lorusso, Vito, Latorre, Agnese, Giotta, Francesco
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Hindawi 2020
Materias:	Review Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7719522/ https://www.ncbi.nlm.nih.gov/pubmed/33312203 http://dx.doi.org/10.1155/2020/9645294

Ejemplares similares

Bevacizumab in the treatment of HER2-negative breast cancer
por: Lorusso, Vito
Publicado: (2008)

Machine learning survival models trained on clinical data to identify high risk patients with hormone responsive HER2 negative breast cancer
por: Fanizzi, Annarita, et al.
Publicado: (2023)

FISH testing of HER2 immunohistochemistry 1+ invasive breast cancer with unfavorable characteristics
por: Petroni, Stella, et al.
Publicado: (2016)

Use of eribulin as an earlier-line chemotherapy for patients with HER2-negative metastatic breast cancer
por: Shingaki, Sumito, et al.
Publicado: (2020)

Treatment Options for Metastatic Urothelial Carcinoma After First-Line Chemotherapy
por: Tassinari, Elisa, et al.
Publicado: (2022)

Randomized phase II study of nab‐paclitaxel as first‐line chemotherapy in patients with HER2‐negative metastatic breast cancer
por: Tamura, Kenji, et al.
Publicado: (2017)

Comparison of Two Chemotherapy Regimens After First-Line Treatment for HER2-Negative Metastatic Gastric Cancer
por: Urakçı, Zuhat, et al.
Publicado: (2023)

Palbociclib: A New Option for Front-Line Treatment of Metastatic, Hormone Receptor–Positive, HER2-Negative Breast Cancer
por: Bowles, Harmony J., et al.
Publicado: (2015)

Predicting of Sentinel Lymph Node Status in Breast Cancer Patients with Clinically Negative Nodes: A Validation Study
por: Fanizzi, Annarita, et al.
Publicado: (2021)

Bevacizumab based chemotherapy in first line treatment of HER2 negative metastatic breast cancer: results of a Moroccan observational institutional study
por: Boulaamane, Lamiaa, et al.
Publicado: (2012)

Early Prediction of Breast Cancer Recurrence for Patients Treated with Neoadjuvant Chemotherapy: A Transfer Learning Approach on DCE-MRIs
por: Comes, Maria Colomba, et al.
Publicado: (2021)

Outcome beyond third-line chemotherapy for metastatic triple-negative breast cancer in the French ESME program
por: Cabel, Luc, et al.
Publicado: (2021)

Metronomic oral chemotherapy with cyclophosphamide plus capecitabine combined with trastuzumab (HEX) as first line therapy of HER-2 positive advanced breast cancer: A phase II trial of the Gruppo Oncologico Italia Meridionale (GOIM)
por: Orlando, Laura, et al.
Publicado: (2020)

Clinical Outcomes with First-line Endocrine Therapy or Chemotherapy in Postmenopausal HR+/HER2− Metastatic Breast Cancer
por: Song, Yan, et al.
Publicado: (2015)

First line chemotherapy plus trastuzumab in metastatic breast cancer HER2 positive - Observational institutional study
por: Aitelhaj, Meryem, et al.
Publicado: (2016)

Assessing the tolerability and efficacy of first-line chemotherapy in elderly patients with metastatic HER2−ve breast cancer
por: Wilson, Thomas, et al.
Publicado: (2019)

All-oral combination of oral vinorelbine and capecitabine as first-line chemotherapy in HER2-negative metastatic breast cancer: an International Phase II Trial
por: Tubiana-Mathieu, N, et al.
Publicado: (2009)

A phase II, multicenter, single-arm trial of eribulin as first-line chemotherapy for HER2-negative locally advanced or metastatic breast cancer
por: Takashima, Tsutomu, et al.
Publicado: (2016)

Efficacy and clinical outcome of chemotherapy and endocrine therapy as first-line treatment in patients with hormone receptor-positive HER2-negative metastatic breast cancer
por: Yuan, Yang, et al.
Publicado: (2023)

Maintenance bevacizumab beyond first-line paclitaxel plus bevacizumab in patients with Her2-negative hormone receptor-positive metastatic breast cancer: efficacy in combination with hormonal therapy
por: Fabi, Alessandra, et al.
Publicado: (2012)

Management of Chemotherapy-Induced Nausea and Vomiting (CINV): A Short Review on the Role of Netupitant-Palonosetron (NEPA)
por: Lorusso, Vito, et al.
Publicado: (2020)

Bevacizumab Added to Neoadjuvant Chemotherapy in HER2-Negative Non-Metastatic Breast Cancer
por: Wan, Guoxing, et al.
Publicado: (2019)

Edoxaban: front-line treatment for brachiocephalic vein thrombosis in primitive mediastinal seminoma: A case report and literature review
por: Fioretti, Agnese Maria, et al.
Publicado: (2022)

Trastuzumab combined with doublet or single-agent chemotherapy as first-line therapy for HER2-positive metastatic breast cancer
por: Yu, Y. F., et al.
Publicado: (2017)

Efficacy and safety of trastuzumab combined with chemotherapy for first-line treatment and beyond progression of HER2-overexpressing advanced breast cancer
por: Li, Huiping, et al.
Publicado: (2016)

Preferences for the sequencing of first-line systemic treatments in metastatic hormone receptor-positive, HER2-negative breast cancer
por: Al Mahmasani, Layal, et al.
Publicado: (2023)

Trastuzumab-based regimens beyond progression: A crucial treatment option for HER2+ advanced/metastatic breast cancer
por: Sanglier, Thibaut, et al.
Publicado: (2022)

A ultrasound-based radiomic approach to predict the nodal status in clinically negative breast cancer patients
por: Bove, Samantha, et al.
Publicado: (2022)

Chemotherapy or endocrine therapy, first-line treatment for patients with hormone receptor-positive HER2-negative metastatic breast cancer in China: a real-world study
por: Yuan, Yang, et al.
Publicado: (2021)

Concept: A randomised multicentre trial of first line chemotherapy comparing three weekly cabazitaxel versus weekly paclitaxel in HER2 negative metastatic breast cancer()()
por: Bahl, Amit, et al.
Publicado: (2022)

Moving beyond first-line treatment options for OCD
por: Paxos, Chris
Publicado: (2022)

Capecitabine Plus Aromatase Inhibitor as First Line Therapy for Hormone Receptor Positive, HER2 Negative Metastatic Breast Cancer
por: Alvarado-Miranda, Alberto, et al.
Publicado: (2023)

The influence on quality of life of intermittent scheduling in first- and second-line chemotherapy of patients with HER2-negative advanced breast cancer
por: Claessens, Anouk K. M., et al.
Publicado: (2019)

The prognostic relevance of HER2-positivity gain in metastatic breast cancer in the ChangeHER trial
por: Pizzuti, Laura, et al.
Publicado: (2021)

The prognostic and therapeutic implications of circulating tumor cell phenotype detection based on epithelial–mesenchymal transition markers in the first-line chemotherapy of HER2-negative metastatic breast cancer
por: Guan, Xiuwen, et al.
Publicado: (2019)

Robustness Evaluation of a Deep Learning Model on Sagittal and Axial Breast DCE-MRIs to Predict Pathological Complete Response to Neoadjuvant Chemotherapy
por: Massafra, Raffaella, et al.
Publicado: (2022)

Adjuvant therapy of endometrial cancer: “taxane or not taxane, this is the question”
por: Lorusso, Vito, et al.
Publicado: (2019)

Second-line Eribulin in Triple Negative Metastatic Breast Cancer patients. Multicentre Retrospective Study: The TETRIS Trial
por: Krasniqi, Eriseld, et al.
Publicado: (2021)

Trastuzumab beyond progression in HER2‐positive metastatic breast cancer
por: Al‐Naqqash, Manwar, et al.
Publicado: (2021)

New schedule of bevacizumab/paclitaxel as first‐line therapy for metastatic HER2‐negative breast cancer in a real‐life setting
por: Cannita, Katia, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_05htkc49b8gqj4m6ql1l0iacgs